Improved quality of life with fremanezumab in Japanese and Korean patients with episodic and chronic migraine: Results of two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group clinical trials

ObjectiveTo evaluate quality of life (QoL) endpoints from two 12‐week trials investigating fremanezumab efficacy and safety in Japanese/Korean patients with chronic (CM) or episodic (EM) migraine.BackgroundMigraine is a leading cause of disability and affects QoL considerably, interfering with work and daily activities, social and family life, and emotional wellbeing.MethodsThis planned exploratory analysis used data from two multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group studies in which Migraine‐Specific QoL (MSQoL; Role Function‐Restrictive [RR], Role Function‐Preventive [RP], and Emotional Function [EF] domains) scores and Patient Global Impression of Change (PGIC) scores were pre‐specified QoL outcomes in individuals receiving monthly or quarterly fremanezumab or placebo. In both trials, MSQoL was assessed at baseline, and MSQoL and PGIC at Weeks 4, 8, and 12. PGIC responders had a score of ≥5 points, indicating significant improvement.ResultsMean baseline MSQoL scores were similar across groups in both CM (N = 565; RR, 60.3–61.5; RP, 78.5–80.0; EF, 69.0–71.4) and EM (N = 353; RR, 68.6–71.1; RP, 83.1–85.7; EF, 76.7–81.9) trials. In the CM trial, all three MSQoL domains improved in both fremanezumab groups at 12 weeks compared with placebo: least squares mean (LSM) and standard error (SE) change from baseline, p versus placebo (quarterly; monthly; placebo): RR 14.9 (1.3), p = 0.030; 15.1 (1.4), p = 0.020; 11.6 (1.3); RP 8.9 (1.1), p = 0.007; 8.6 (1.1), p = 0.013; 5.4 (1.1); EF 13.3 (1.5), p